 |
|
Long-Acting  2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma
A Randomized Controlled Trial
Stephen C. Lazarus, MD;
Homer A. Boushey, MD;
John V. Fahy, MD;
Vernon M. Chinchilli, PhD;
Robert F. Lemanske, Jr, MD;
Christine A. Sorkness, PharmD;
Monica Kraft, MD;
James E. Fish, MD;
Stephen P. Peters, MD, PhD;
Timothy Craig, DO;
Jeffrey M. Drazen, MD;
Jean G. Ford, MD;
Elliot Israel, MD;
Richard J. Martin, MD;
Elizabeth A. Mauger, PhD;
Sami A. Nachman, MD;
Joseph D. Spahn, MD;
Stanley J. Szefler, MD;
for the Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute
JAMA. 2001;285:2583-2593.
Context Long-acting  2-agonists are prescribed for patients with persistent asthma and are sometimes used without inhaled corticosteroids (ICSs). No evidence exists, however, to support their use as monotherapy in adults with persistent asthma.
Objective To examine the effectiveness of salmeterol xinafoate, a long-acting 2-agonist, as replacement therapy in patients whose asthma is well controlled by low-dose triamcinolone acetonide, an ICS.
Design and Setting A 28-week, randomized, blinded, placebo-controlled, parallel group trial conducted at 6 National Institutes of Health–sponsored, university-based ambulatory care centers from February 1997 to January 1999.
Participants One hundred sixty-four patients aged 12 through 65 years with persistent asthma that was well controlled during a 6-week run-in period of treatment with inhaled triamcinolone (400 µg twice per day).
Interventions Patients were randomly assigned to continue triamcinolone therapy (400 µg twice per day; n = 54) or switch to salmeterol (42 µg twice per day; n = 54) or to placebo (n = 56) for 16 weeks, after which all patients received placebo for an additional 6-week run-out period.
Main Outcome Measures Change in morning and evening peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), self-assessed asthma symptom scores, rescue albuterol use, asthma-specific quality-of-life scores, treatment failure, asthma exacerbation, bronchial reactivity, and markers of airway inflammation, compared among the 3 treatment groups.
Results During the 16-week randomized treatment period, no significant differences between the salmeterol and triamcinolone groups were observed for conventional outcomes of clinical studies of asthma therapy—morning PEF, evening PEF, asthma symptom scores, rescue albuterol sulfate use, or quality of life. Both active treatments were superior to placebo. However, the salmeterol group had more treatment failures than the triamcinolone group (13/54 [24%] vs 3/54 [6%]; P = .004), as well as more asthma exacerbations (11/54 [20%] vs 4/54 [7%]; P = .04), greater increases in median (interquartile range) sputum eosinophils (2.4% [0.0% to 10.6%] vs -0.1% [-0.7% to 0.3%]; P<.001), eosinophil cationic protein (71 [-2 to 430] U/L vs -4 [-31 to 56] U/L; P = .005), and tryptase (3.1 [2.1 to 7.6] ng/mL vs 0.0 [0.0 to 0.7] ng/mL; P<.001). The duration of benefit when patients were switched from active treatment to placebo after 22 weeks of randomized treatment was not significantly longer in the triamcinolone group than in the salmeterol group.
Conclusions Patients with persistent asthma well controlled by low doses of triamcinolone cannot be switched to salmeterol monotherapy without risk of clinically significant loss of asthma control.
Author Affiliations: University of California, San Francisco (Drs Lazarus, Boushey, and Fahy); Milton S. Hershey Medical Center, Hershey, Pa (Drs Chinchilli, Craig, and Mauger); University of Wisconsin Medical School (Dr Lemanske) and School of Pharmacy (Dr Sorkness), Madison; National Jewish Medical and Research Center, Denver, Colo (Drs Kraft, Martin, Spahn, and Szefler); Thomas Jefferson University, Philadelphia, Pa (Drs Fish and Peters); Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Drs Drazen and Israel); and Harlem Hospital Center, New York, NY (Drs Ford and Nachman).
RELATED LETTER
Salmeterol and Inhaled Corticosteroids in Patients With Persistent Asthma
Jeffrey R. Botkin, Ellen Clayton, Robert Nelson, Benjamin Wilfond, Mark A. Munger, Franklin G. Miller, Andrew F. Shorr, Lainie Friedman Ross, Stephen J. Fowler, Brian J. Lipworth, Stephen C. Lazarus, and Robert F. Lemanske, Jr
JAMA. 2001;286(24):3075-3078.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial
Robert F. Lemanske, Jr, Christine A. Sorkness, Elizabeth A. Mauger, Stephen C. Lazarus, Homer A. Boushey, John V. Fahy, Jeffrey M. Drazen, Vernon M. Chinchilli, Timothy Craig, James E. Fish, Jean G. Ford, Elliot Israel, Monica Kraft, Richard J. Martin, Sami A. Nachman, Stephen P. Peters, Joseph D. Spahn, Stanley J. Szefler, and for the Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute
JAMA. 2001;285(20):2594-2603.
ABSTRACT
| FULL TEXT
Therapeutic Options for Persistent Asthma
Stephen T. Holgate
JAMA. 2001;285(20):2637-2639.
EXTRACT
| FULL TEXT
May 23/30, 2001
JAMA. 2001;285(20):2655-2656.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A new perspective on concepts of asthma severity and control
Taylor et al.
Eur Respir J 2008;32:545-554.
ABSTRACT
| FULL TEXT
Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits
Bjermer
Therapeutic Advances in Respiratory Disease 2008;2:149-161.
ABSTRACT
Global strategy for asthma management and prevention: GINA executive summary
Bateman et al.
Eur Respir J 2008;31:143-178.
ABSTRACT
| FULL TEXT
Differentiating COPD From Asthma in Clinical Practice
Chang and Mosenifar
J Intensive Care Med 2007;22:300-309.
ABSTRACT
Randomized Comparison of Strategies for Reducing Treatment in Mild Persistent Asthma
The American Lung Association Asthma Clinical Rese
NEJM 2007;356:2027-2039.
ABSTRACT
| FULL TEXT
Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma
Papi et al.
NEJM 2007;356:2040-2052.
ABSTRACT
| FULL TEXT
Ethical Issues Confronted In Pulmonary Clinical Trials
Wise
Proc Am Thorac Soc 2007;4:200-205.
ABSTRACT
| FULL TEXT
Combination Therapy with a Long-Acting beta-Agonist and a Leukotriene Antagonist in Moderate Asthma
Deykin et al.
Am. J. Respir. Crit. Care Med. 2007;175:228-234.
ABSTRACT
| FULL TEXT
Sequence, Haplotype, and Association Analysis of ADRbeta2 in a Multiethnic Asthma Case-Control Study
Hawkins et al.
Am. J. Respir. Crit. Care Med. 2006;174:1101-1109.
ABSTRACT
| FULL TEXT
Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids.
Ernst et al.
ANN INTERN MED 2006;145:692-694.
ABSTRACT
| FULL TEXT
A Safety Review of Long-Acting {beta}2-Agonists in Patients With Asthma
Rider and Craig
JAOA: Journal of the American Osteopathic Association 2006;106:562-567.
ABSTRACT
| FULL TEXT
Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths
Salpeter et al.
ANN INTERN MED 2006;144:904-912.
ABSTRACT
| FULL TEXT
beta-Adrenoceptor Polymorphisms: Focus Moves to Long-Acting beta-Agonists.
Tattersfield and Harrison
Am. J. Respir. Crit. Care Med. 2006;173:473-474.
FULL TEXT
beta-Adrenergic Receptor Polymorphisms and Response to Salmeterol
Wechsler et al.
Am. J. Respir. Crit. Care Med. 2006;173:519-526.
ABSTRACT
| FULL TEXT
Coexistent chronic conditions and asthma quality of life: a population-based study.
Adams et al.
Chest 2006;129:285-291.
ABSTRACT
| FULL TEXT
Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003
Becker et al.
CMAJ 2005;173:S3-S11.
FULL TEXT
Traditional and patient-centred outcomes with three classes of asthma medication
Jenkins et al.
Eur Respir J 2005;26:36-44.
ABSTRACT
| FULL TEXT
Asthma: One Hundred Years of Treatment and Onward
Chu and Drazen
Am. J. Respir. Crit. Care Med. 2005;171:1202-1208.
ABSTRACT
| FULL TEXT
What Is New with the {beta}2-Agonists: Issues in the Management of Asthma
Kelly
The Annals of Pharmacotherapy 2005;39:931-938.
ABSTRACT
| FULL TEXT
Daily versus As-Needed Corticosteroids for Mild Persistent Asthma
Boushey et al.
NEJM 2005;352:1519-1528.
ABSTRACT
| FULL TEXT
Asthma Steroid Pharmacogenetics: A Study Strategy to Identify Replicated Treatment Responses
Weiss et al.
Proc Am Thorac Soc 2004;1:364-367.
ABSTRACT
| FULL TEXT
Review: inhaled long acting {beta}2 agonists are effective and safe in stable chronic asthma
Parameswaran
EDUCATION AND PRACTICE 2004;89:ep80-ep80.
FULL TEXT
Update on National Asthma Education and Prevention Program Pediatric Asthma Treatment Recommendations
Eid
CLIN PEDIATR 2004;43:793-802.
ABSTRACT
Review: inhaled long acting {beta}2 agonists are effective and safe in stable chronic asthma
Parameswaran
Evid. Based Med. 2004;9:139-139.
FULL TEXT
Therapeutic Responses in Asthma and COPD: Bronchodilators
Donohue
Chest 2004;126:125S-137S.
ABSTRACT
| FULL TEXT
Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis
Sin et al.
JAMA 2004;292:367-376.
ABSTRACT
| FULL TEXT
Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids
Tantisira et al.
Hum Mol Genet 2004;13:1353-1359.
ABSTRACT
| FULL TEXT
Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma
Salpeter et al.
ANN INTERN MED 2004;140:802-813.
ABSTRACT
| FULL TEXT
Asthma Exacerbations and Formoterol
Rissmiller et al.
Chest 2004;125:1590-1591.
FULL TEXT
Ethical Assessment of Clinical Asthma Trials Including Children Subjects
Coffey et al.
Pediatrics 2004;113:87-94.
ABSTRACT
| FULL TEXT
Airway Tissue Mast Cells in Persistent Asthma: Predictor of Treatment Failure When Patients Discontinue Inhaled Corticosteroids
Kraft et al.
Chest 2003;124:42-50.
ABSTRACT
| FULL TEXT
Airway-stabilizing effect of long-acting {beta}2-agonists as add-on therapy to inhaled corticosteroids
Currie et al.
QJM 2003;96:435-440.
ABSTRACT
| FULL TEXT
Effects of Montelukast on Surrogate Inflammatory Markers in Corticosteroid-treated Patients with Asthma
Currie et al.
Am. J. Respir. Crit. Care Med. 2003;167:1232-1238.
ABSTRACT
| FULL TEXT
Management of asthma in adults: current therapy and future directions
Green et al.
Postgrad. Med. J. 2003;79:259-267.
ABSTRACT
| FULL TEXT
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT
Long-Acting {beta}2-Agonist Monotherapy Versus Continued Therapy with Inhaled Corticosteroids in Patients with Persistent Asthma (SOCS)
Goldsobel
Pediatrics 2002;110:457-457.
FULL TEXT
ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB
Evid. Based Med. 2002;7:3-3.
FULL TEXT
Salmeterol and Inhaled Corticosteroids in Patients With Persistent Asthma
Botkin et al.
JAMA 2001;286:3075-3078.
FULL TEXT
Inhaled Long-Acting {beta}2-Agonists in Asthma Treatment
JWatch General 2001;2001:1-1.
FULL TEXT
Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial
Lemanske et al.
JAMA 2001;285:2594-2603.
ABSTRACT
| FULL TEXT
Therapeutic Options for Persistent Asthma
Holgate
JAMA 2001;285:2637-2639.
FULL TEXT
|
